Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-2.03 Insider Own1.50% Shs Outstand91.69M Perf Week10.65%
Market Cap2.61B Forward P/E- EPS next Y-1.94 Insider Trans-3.30% Shs Float84.53M Perf Month40.74%
Income-182.70M PEG- EPS next Q-0.45 Inst Own79.10% Short Float10.09% Perf Quarter-7.12%
Sales190.30M P/S13.73 EPS this Y-137.10% Inst Trans-0.23% Short Ratio5.62 Perf Half Y-28.08%
Book/sh4.05 P/B7.18 EPS next Y-65.80% ROA-22.60% Target Price36.29 Perf Year-30.64%
Cash/sh6.06 P/C4.80 EPS next 5Y- ROE-44.50% 52W Range18.12 - 57.21 Perf YTD-21.57%
Dividend- P/FCF28.41 EPS past 5Y-8.20% ROI-40.20% 52W High-49.15% Beta0.99
Dividend %- Quick Ratio3.60 Sales past 5Y-0.50% Gross Margin94.10% 52W Low60.54% ATR1.06
Employees599 Current Ratio3.70 Sales Q/Q57.40% Oper. Margin-95.20% RSI (14)77.44 Volatility4.40% 4.75%
OptionableYes Debt/Eq0.14 EPS Q/Q11.90% Profit Margin-96.00% Rel Volume0.62 Prev Close28.80
ShortableYes LT Debt/Eq0.11 EarningsMay 10 AMC Payout- Avg Volume1.52M Price29.09
Recom2.50 SMA2019.58% SMA5030.91% SMA200-20.68% Volume943,272 Change1.01%
Apr-07-21Downgrade Mizuho Buy → Neutral $72 → $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral
Mar-31-21Upgrade BofA Securities Neutral → Buy $47
Mar-02-21Downgrade Jefferies Buy → Hold $75 → $45
Feb-01-21Initiated H.C. Wainwright Buy $58
Oct-26-20Initiated Raymond James Underperform
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Jun-21-21 06:18AM  
Jun-17-21 08:29AM  
07:00AM  
Jun-16-21 08:00AM  
Jun-14-21 07:39PM  
Jun-12-21 06:28PM  
Jun-11-21 05:00PM  
10:36AM  
10:10AM  
10:00AM  
09:40AM  
06:00AM  
Jun-10-21 11:57PM  
09:49PM  
07:25PM  
07:00PM  
03:17PM  
01:50PM  
12:03PM  
11:50AM  
10:34AM  
10:00AM  
10:00AM  
05:40AM  
Jun-09-21 09:39PM  
09:28PM  
09:00PM  
08:50PM  
07:18PM  
06:59PM  
06:52PM  
05:21PM  
04:20PM  
02:54PM  
02:15PM  
12:58PM  
11:30AM  
11:00AM  
10:32AM  
05:36AM  
12:10AM  
Jun-08-21 10:51PM  
10:38PM  
08:43PM  
07:15PM  
06:10PM  
03:15PM  
02:30PM  
02:00PM  
01:45PM  
01:45PM  
01:14PM  
12:36PM  
11:00AM  
10:30AM  
09:40AM  
09:30AM  
09:11AM  
05:40AM  
Jun-07-21 11:03PM  
08:36PM  
07:09PM  
06:45PM  
12:40PM  
12:30PM  
11:10AM  
11:00AM  
11:00AM  
09:35AM  
05:40AM  
Jun-06-21 12:30PM  
10:30AM  
08:48AM  
Jun-05-21 06:47PM  
03:15PM  
03:08PM  
08:23AM  
Jun-04-21 10:00PM  
05:00PM  
03:45PM  
01:45PM  
01:20PM  
11:06AM  
11:00AM  
09:30AM  
05:40AM  
Jun-03-21 10:00PM  
08:49PM  
08:20PM  
07:14PM  
03:40PM  
02:05PM  
01:33PM  
12:00PM  
10:14AM  
06:18AM  
Jun-02-21 10:01PM  
08:10PM  
07:40PM  
07:10PM  
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cotroneo PatSVP, Finance and CFOJun 15Sale25.624,053103,838276,677Jun 17 09:25 PM
KEARNS THOMAS F JRDirectorMar 11Option Exercise3.5018,00063,000166,164Mar 15 06:22 PM
KEARNS THOMAS F JRDirectorMar 11Sale35.0218,000630,360148,164Mar 15 06:22 PM
Kurkijarvi KaleviDirectorFeb 17Option Exercise28.656,000171,90039,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorFeb 17Sale52.406,000314,38333,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorJan 19Option Exercise19.056,000114,30039,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 19Sale43.386,000260,28033,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 14Option Exercise19.055,999114,28139,099Jan 15 08:02 PM
Kurkijarvi KaleviDirectorJan 14Sale40.045,999240,20033,100Jan 15 08:02 PM
Schoeneck James ADirectorJan 04Option Exercise9.786,00058,65015,400Jan 06 07:08 PM
Kurkijarvi KaleviDirectorDec 28Option Exercise18.346,001110,05939,101Dec 30 06:07 PM
Kurkijarvi KaleviDirectorDec 28Sale40.406,001242,45533,100Dec 30 06:07 PM
Yu K PeonyChief Medical OfficerDec 16Sale41.613,350139,394192,292Dec 17 07:06 PM
Cotroneo PatSVP, Finance and CFODec 15Sale43.603,068133,765266,144Dec 17 07:04 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyNov 17Option Exercise14.577,082103,220134,495Nov 19 04:52 PM
Yu K PeonyChief Medical OfficerSep 16Sale44.013,351147,478198,934Sep 18 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 15Sale43.633,070133,944272,226Sep 17 06:03 PM
Cotroneo PatSVP, Finance and CFOSep 03Option Exercise23.3015,004349,582293,314Sep 04 04:30 PM
Yu K PeonyChief Medical OfficerSep 03Option Exercise18.0010,000180,000215,576Sep 04 04:33 PM
Yu K PeonyChief Medical OfficerSep 03Sale50.8910,000508,900205,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Sale50.9115,004763,854278,310Sep 04 04:30 PM
Schoeneck James ADirectorAug 20Option Exercise5.956,00035,70015,400Aug 21 05:58 PM
Cotroneo PatSVP, Finance and CFOAug 11Option Exercise18.727,250135,712278,310Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Option Exercise19.3922,554437,322293,614Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Sale48.0022,5541,082,592271,060Aug 11 04:34 PM
Yu K PeonyChief Medical OfficerJul 24Sale42.353,351141,915205,576Jul 28 07:33 PM